2013-04-09
Yesterday’s Picks |
|
| YGE | JASO | CSUN | HSOL | STP | LDK | CSIQ | ASTI | JKS | TSL |
|---|---|---|---|---|---|---|---|---|---|
| 21.08% | 19.51% | 9.56% | 10.77% | 29.17% | 23.36% | 10.26% | 4.97% | 16.00% | 14.58% |
 |
|
 |
|
|
|
|
|
|
|
75% Gains in just 3 days!
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
See our picks from yesterday, get fresh picks everyday!
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Goff, Corp. (A Development Stage Company)
ZERO to $167 million in 3 months!
See how a mining genius, the boy with a golden touch built a multi-million dollar global mining empire from scratch!
Gold mining App: Leave your picks, shovels and bulldozers at home. Gold mining today is as simple as developing an App for Apple!
Mining made Easy: Mining is as easy as building an app for Android. Learn from this 30 year old genius, who probably doesn’t know the difference between a rock and cow dung, however, managed to build a global mining giant with operations in Africa, Europe, Latin America and the United States.
Is he gonna share his secret strategy? Don’t hold your breath. However, we managed to find some golden nuggets buried deep in the regulatory filings.
As of December 31, 2012,
Cash Balance and Total Assets of $5,653 (Five Thousand Six Hundred Fifty Three Dollars)
As of Apr 5, 2013
Market Value/Market Cap $167 Million Dollars!
Source: Google Finance
GOFF, Goff Corp.
| Range | 0.57 – 0.62 |
| 52 week | 0.13 – 0.62 |
| Open | 0.58 |
| Vol / Avg. | 22.00M/32.46M |
| Mkt cap | 167.37M |
| Zero to $167 million in 3 months! WOW! |
| Trans Date | Filer | Ownership | Type | Price | Shares | |
|---|---|---|---|---|---|---|
| Feb 28, 2013 | CALASSE WARWICK ADAM Officer |
direct | Acquisition (Non Open Market) | 0.00 | 100,000,000 | |
| Feb 26, 2013 | CALASSE WARWICK ADAM Officer |
direct | NA | 0.00 | ||
GOING CONCERN:
These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2012, the Company has not recognized any revenue, and has a working capital deficit of $19,911 and an accumulated deficit of $48,261.
The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
RELATED PARTY TRANSACTIONS:
As at December 31, 2012, the Company owes $24,814 to the President and Direct or of the Company.
Source: SEC, Finra, Google, Edgar, OxBridge Research, Daily Stock Deals
Tags: zero to 167 million dollars, extreme mining, mining made easy, 3 month mining crash course, gold mining app, mining gold,GOFF
MILTON, Ga., April 4, 2013 (GLOBE NEWSWIRE) — Exide Technologies (XIDE) (www.exide.com), a global leader in stored electrical energy solutions, announced today that the financial advisory firm of Lazard has been retained to advise the company on financing alternatives to maximize the value of the company for all stakeholders. The company does not anticipate making any further announcements regarding its review until the process is complete. In addition, the company expects that fiscal 2013 fourth quarter free cash flow will be approximately $50 million, exceeding prior guidance of $30 million, with total liquidity (cash and availability under credit lines) at March 31, 2013 of greater than $230 million. These amounts are all subject to final audit and, therefore, could be subject to change.
http://www.dailystockdeals.com/featured-deal/blog
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE
(Reuters) – Fannie Mae, helped by the housing market’s continued recovery, posted an $17.2 billion annual profit for 2012 on Tuesday, its largest ever yearly gain and its first in six years.
Mortgage finance giant Fannie Mae and its smaller sibling company Freddie Mac are returning to health as home prices have leveled off and mortgage delinquencies have dampened.
Fannie Mae said in its filing that it did not book a tax-related gain that could have been as much as $59 billion that would have fueled earnings and allowed the company to make an enormous one-time payment to the U.S. Treasury to reduce remaining bailout funds.
The company had missed its March 18 filing deadline for its fourth-quarter financial results and said it needed more time to analyze those so-called deferred tax assets, which are unused credits that can be used to cover future tax bills.
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Source: Fannie Mae, Reuters, OxBridge Research, Daily Stock Deals
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system.
http://www.dailystockdeals.com/topten/hot-biotechnology-stocks-idra-04-01-2013
Source: company, OxBridge Research, Daily Stock Deals
CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Idera Pharmaceuticals, Inc. (IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is in clinical development for the treatment of autoimmune diseases.
During the first quarter of 2013, the Company completed the escalating single-dose portion of the Phase 1 trial of IMO-8400 and has now completed patient dosing in the multiple-dose portion of the trial. The multiple-dose portion of the trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment of four weekly doses. The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013.
Source: company, OxBridge Research, Daily Stock Deals
HEB, Hemispherx Biopharma
Hemispherx Biopharma, HEB, is a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Its products include Ampligen, an experimental drug under clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hepatitis B, human immunodeficiency virus (HIV), renal cell carcinoma, and malignant melanoma; Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, an experimental low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza and other emerging viral diseases.
Don’t miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!
Source: company, OxBridge Research, Daily Stock Deals